Mei Pharma Inc (MEIP) 6.06 $MEIP
Metastatic Prostate Cancer Therapeutics Pipeline Review 2015 - 12 Companies & 19 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2btq2g/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actinium Pharmaceuticals, Inc. - Camurus AB - Colby Pharmaceutical Company - Eli Lilly and Company - Fountain Biopharma Inc. - Johnson & Johnson - MedImmune, LLC - MEI Pharma, Inc. - OncoMax - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. - ValiRx Plc Drug Profiles - abiraterone acetate - Actimab-P - CADD-522 - Cell Therapy to Target PSMA for Metastatic Prostate Cancer - CPC-410 - FB-704A - KGP-94 - leuprolide acetate - LU-901 - LY-2495655 - MEDI-6469 - MIP-1095 - MVI-118 - OMRCA-01 - pracinostat - Recombinant Protein for Oncology - VAC-1 - Vaccine For Oncolytic Newcastle Disease Virus - VAL-201 For more information visit http://www.researchandmarkets.com/research/2btq2g/metastatic
OXGN: 1.73 (-0.07), PGNX: 6.43 (-0.66), JNJ: 100.72 (+1.51), ATNM: 2.45 (-0.22), LLY: 71.08 (+1.19), MEIP: 6.06 (-0.07)
Heavy Institutional Buying Is Occurring In MEI Pharma, Topline Data Due In Mid-March
StockMatusow - Seeking Alpha - Thu Feb 26, 7:30AM CST
Written by Scott Matusow and Michael Kovar MEI Pharma (NASDAQ: MEIP ) specializes in oncology and is currently focused on the clinical development of its lead drug candidate Pracinostat. Pracinostat is an orally available histone deacetylase...
ONTX: 2.23 (-0.02), MEIP: 6.06 (-0.07), CELG: 120.36 (+2.63)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:16AM CST
ANET: 71.25 (+2.20), FUEL: 9.37 (-0.08), EPRS: 10.00 (+0.04), ASTI: 1.15 (-0.03), MEIP: 6.06 (-0.07), OESX: 3.02 (+0.05), GENE: 4.43 (-0.28), CLSN: 2.53 (-0.11), NVO: 48.89 (+1.29), SAAS: 10.82 (+0.06), CRC: 6.62 (-0.15), CLRX: 1.07 (unch), NDLS: 17.83 (+0.34), TRUE: 17.42 (+0.01)
4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
at The Street - Tue Feb 10, 1:01PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
AMRN: 3.01 (+0.11), FOLD: 9.37 (+0.12), MEIP: 6.06 (-0.07), EXEL: 2.64 (unch)
5 Under-$10 Health Care Stocks Setting Up to Trade Higher
at The Street - Thu Jan 29, 6:00AM CST
These setups often produce monster moves higher in very short time frames.
APT: 2.30 (-0.10), CDNA: 6.57 (-0.09), GNCA: 9.42 (unch), IG: 8.15 (-0.02), MEIP: 6.06 (-0.07)
MEI Pharma (MEIP) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:41AM CST
MEI Pharma (MEIP) Is in Oversold Territory: What’s Next?
MEIP: 6.06 (-0.07)
MEI Pharma: A Rare Hidden Gem With Impressive Clinical Data
Stock Doctor - Seeking Alpha - Wed Jan 21, 12:11PM CST
I'm always on the hunt for bargain biotech stocks, especially those that have underappreciated best-in-class drugs with small market caps. Typically, these stocks have a lot of room to run on upcoming catalysts or clinical trial results. Those that...
MEIP: 6.06 (-0.07)
NIRI San Diego Elects 2015 Board Members
PR Newswire - Mon Dec 22, 3:05PM CST
The San Diego Chapter of the National Investor Relations Institute (NIRI San Diego) has announced the election of its board of directors for 2015. The incoming board includes a newly formed, novel Co-president position to appropriately balance the leadership skills of three returning board members. The chapter has also formed an advisory committee comprised of out-going board members Gwen Rosenberg, Jane Booth, Karen Fisher, and John Stoepler, to recognize their long-term contributions to NIRI San Diego.
RGLS: 18.69 (-0.41), ENTR: 2.97 (-0.03), MEIP: 6.06 (-0.07)
MEI Pharma Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome
PR Newswire - Mon Dec 22, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the clinical response milestone has been reached in the Company's ongoing Phase II study of its investigational drug candidate Pracinostat in combination with a hypomethylating agent (HMA) in patients with myelodysplastic syndrome (MDS) who previously failed treatment with single-agent HMA.
MEIP: 6.06 (-0.07)
MEI Pharma concludes public offering of 11.5m common shares, including exercise in underwriters' option
M2 - Thu Dec 18, 7:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) said on Wednesday that it has closed the public offering of 11,500,000 shares of its common stock.
MEIP: 6.06 (-0.07)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 101.10 (+1.49), GERN: 4.16 (-0.18), INCY: 90.90 (+1.59), AZN: 68.95 (+1.60), LLY: 71.08 (+1.19), BMY: 67.82 (+0.95), NVS: 97.90 (+0.86), MEIP: 6.06 (-0.07), CELGZ: 3.02 (-0.03), XLRN: 41.20 (unch)
MEI Pharma Completes Public Offering of Common Stock
PR Newswire - Wed Dec 17, 3:05PM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares of common stock that were issued upon exercise, in full, of the option to purchase additional shares granted to the underwriters. Exercise of the full option to purchase additional shares by the underwriters increased the gross proceeds to the Company, before underwriting discounts and expenses, from approximately $40.0 million to approximately $46.0 million.
MEIP: 6.06 (-0.07)
MEI Pharma prices public offering of common shares at USD4.00 per share
M2 - Mon Dec 15, 6:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) said on Friday that it has priced public offering of 10,000,000 shares of its common stock.
MEIP: 6.06 (-0.07)
Nasdaq stocks posting largest volume increases
AP - Fri Dec 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ISIG: 2.91 (unch), HCCI: 13.12 (-0.07), ANCB: 22.45 (+0.08), MEIP: 6.06 (-0.07)
MEI Pharma Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Fri Dec 12, 7:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of $4.00 per share, for total gross proceeds (before underwriting discount and commissions and estimated expenses) of approximately $40 million. The Company has granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of its common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.
MEIP: 6.06 (-0.07)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 23.94 (+0.55), CLDN: 26.71 (+0.02), BRID: 7.76 (-0.27), HCCI: 13.12 (-0.07), MIND: 5.37 (-0.06), ROSE: 16.68 (-0.37), OBAS: 6.19 (-0.02), MEIP: 6.06 (-0.07), IESC: 7.94 (+0.13), SRPT: 13.97 (-0.14), CONN: 26.99 (-0.40), LINE: 10.77 (-0.43), DGLY: 11.40 (-0.44)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 1.50 (+0.02), FRO: 2.50 (+0.05), ABCO: 53.90 (+0.69), ZAZA: 1.55 (-0.06), JMEI: 13.02 (-0.05), SGMO: 17.14 (-0.26), TGTX: 17.67 (+0.34), MEI: 44.15 (-0.14), WLT: 0.43 (+0.10), NSPR: 0.28 (-0.02), VII: 1.52 (+0.06), CVTI: 34.50 (-2.05), MEIP: 6.06 (-0.07), ALDR: 25.95 (+0.60), CALA: 13.39 (+0.37), CGG: 5.79 (-0.23), SPP: 1.90 (-0.10), DSCO: 1.56 (-0.14), KPTI: 30.40 (+2.32), HBOS: 26.53 (+0.39)
MEI Pharma anticipates USD45m from public offering of common shares
M2 - Thu Dec 11, 6:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) announced on Wednesday that it intends to offer up to USD45m shares of its common stock in a public offering.
MEIP: 6.06 (-0.07)
MEI Pharma Announces $45 Million Proposed Public Offering of Common Stock
PR Newswire - Wed Dec 10, 3:01PM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer up to $45,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
MEIP: 6.06 (-0.07)
Metastatic Prostate Cancer Therapeutics Pipeline Review 2015 - 12 Companies & 19 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2btq2g/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actinium Pharmaceuticals, Inc. - Camurus AB - Colby Pharmaceutical Company - Eli Lilly and Company - Fountain Biopharma Inc. - Johnson & Johnson - MedImmune, LLC - MEI Pharma, Inc. - OncoMax - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. - ValiRx Plc Drug Profiles - abiraterone acetate - Actimab-P - CADD-522 - Cell Therapy to Target PSMA for Metastatic Prostate Cancer - CPC-410 - FB-704A - KGP-94 - leuprolide acetate - LU-901 - LY-2495655 - MEDI-6469 - MIP-1095 - MVI-118 - OMRCA-01 - pracinostat - Recombinant Protein for Oncology - VAC-1 - Vaccine For Oncolytic Newcastle Disease Virus - VAL-201 For more information visit http://www.researchandmarkets.com/research/2btq2g/metastatic
OXGN: 1.73 (-0.07), PGNX: 6.43 (-0.66), JNJ: 100.72 (+1.51), ATNM: 2.45 (-0.22), LLY: 71.08 (+1.19), MEIP: 6.06 (-0.07)
Heavy Institutional Buying Is Occurring In MEI Pharma, Topline Data Due In Mid-March
StockMatusow - Seeking Alpha - Thu Feb 26, 7:30AM CST
Written by Scott Matusow and Michael Kovar MEI Pharma (NASDAQ: MEIP ) specializes in oncology and is currently focused on the clinical development of its lead drug candidate Pracinostat. Pracinostat is an orally available histone deacetylase...
ONTX: 2.23 (-0.02), MEIP: 6.06 (-0.07), CELG: 120.36 (+2.63)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:16AM CST
ANET: 71.25 (+2.20), FUEL: 9.37 (-0.08), EPRS: 10.00 (+0.04), ASTI: 1.15 (-0.03), MEIP: 6.06 (-0.07), OESX: 3.02 (+0.05), GENE: 4.43 (-0.28), CLSN: 2.53 (-0.11), NVO: 48.89 (+1.29), SAAS: 10.82 (+0.06), CRC: 6.62 (-0.15), CLRX: 1.07 (unch), NDLS: 17.83 (+0.34), TRUE: 17.42 (+0.01)
4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
at The Street - Tue Feb 10, 1:01PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
AMRN: 3.01 (+0.11), FOLD: 9.37 (+0.12), MEIP: 6.06 (-0.07), EXEL: 2.64 (unch)
5 Under-$10 Health Care Stocks Setting Up to Trade Higher
at The Street - Thu Jan 29, 6:00AM CST
These setups often produce monster moves higher in very short time frames.
APT: 2.30 (-0.10), CDNA: 6.57 (-0.09), GNCA: 9.42 (unch), IG: 8.15 (-0.02), MEIP: 6.06 (-0.07)
MEI Pharma (MEIP) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:41AM CST
MEI Pharma (MEIP) Is in Oversold Territory: What’s Next?
MEIP: 6.06 (-0.07)
MEI Pharma: A Rare Hidden Gem With Impressive Clinical Data
Stock Doctor - Seeking Alpha - Wed Jan 21, 12:11PM CST
I'm always on the hunt for bargain biotech stocks, especially those that have underappreciated best-in-class drugs with small market caps. Typically, these stocks have a lot of room to run on upcoming catalysts or clinical trial results. Those that...
MEIP: 6.06 (-0.07)
NIRI San Diego Elects 2015 Board Members
PR Newswire - Mon Dec 22, 3:05PM CST
The San Diego Chapter of the National Investor Relations Institute (NIRI San Diego) has announced the election of its board of directors for 2015. The incoming board includes a newly formed, novel Co-president position to appropriately balance the leadership skills of three returning board members. The chapter has also formed an advisory committee comprised of out-going board members Gwen Rosenberg, Jane Booth, Karen Fisher, and John Stoepler, to recognize their long-term contributions to NIRI San Diego.
RGLS: 18.69 (-0.41), ENTR: 2.97 (-0.03), MEIP: 6.06 (-0.07)
MEI Pharma Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome
PR Newswire - Mon Dec 22, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the clinical response milestone has been reached in the Company's ongoing Phase II study of its investigational drug candidate Pracinostat in combination with a hypomethylating agent (HMA) in patients with myelodysplastic syndrome (MDS) who previously failed treatment with single-agent HMA.
MEIP: 6.06 (-0.07)
MEI Pharma concludes public offering of 11.5m common shares, including exercise in underwriters' option
M2 - Thu Dec 18, 7:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) said on Wednesday that it has closed the public offering of 11,500,000 shares of its common stock.
MEIP: 6.06 (-0.07)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 101.10 (+1.49), GERN: 4.16 (-0.18), INCY: 90.90 (+1.59), AZN: 68.95 (+1.60), LLY: 71.08 (+1.19), BMY: 67.82 (+0.95), NVS: 97.90 (+0.86), MEIP: 6.06 (-0.07), CELGZ: 3.02 (-0.03), XLRN: 41.20 (unch)
MEI Pharma Completes Public Offering of Common Stock
PR Newswire - Wed Dec 17, 3:05PM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares of common stock that were issued upon exercise, in full, of the option to purchase additional shares granted to the underwriters. Exercise of the full option to purchase additional shares by the underwriters increased the gross proceeds to the Company, before underwriting discounts and expenses, from approximately $40.0 million to approximately $46.0 million.
MEIP: 6.06 (-0.07)
MEI Pharma prices public offering of common shares at USD4.00 per share
M2 - Mon Dec 15, 6:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) said on Friday that it has priced public offering of 10,000,000 shares of its common stock.
MEIP: 6.06 (-0.07)
Nasdaq stocks posting largest volume increases
AP - Fri Dec 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ISIG: 2.91 (unch), HCCI: 13.12 (-0.07), ANCB: 22.45 (+0.08), MEIP: 6.06 (-0.07)
MEI Pharma Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Fri Dec 12, 7:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of $4.00 per share, for total gross proceeds (before underwriting discount and commissions and estimated expenses) of approximately $40 million. The Company has granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of its common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.
MEIP: 6.06 (-0.07)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 23.94 (+0.55), CLDN: 26.71 (+0.02), BRID: 7.76 (-0.27), HCCI: 13.12 (-0.07), MIND: 5.37 (-0.06), ROSE: 16.68 (-0.37), OBAS: 6.19 (-0.02), MEIP: 6.06 (-0.07), IESC: 7.94 (+0.13), SRPT: 13.97 (-0.14), CONN: 26.99 (-0.40), LINE: 10.77 (-0.43), DGLY: 11.40 (-0.44)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 1.50 (+0.02), FRO: 2.50 (+0.05), ABCO: 53.90 (+0.69), ZAZA: 1.55 (-0.06), JMEI: 13.02 (-0.05), SGMO: 17.14 (-0.26), TGTX: 17.67 (+0.34), MEI: 44.15 (-0.14), WLT: 0.43 (+0.10), NSPR: 0.28 (-0.02), VII: 1.52 (+0.06), CVTI: 34.50 (-2.05), MEIP: 6.06 (-0.07), ALDR: 25.95 (+0.60), CALA: 13.39 (+0.37), CGG: 5.79 (-0.23), SPP: 1.90 (-0.10), DSCO: 1.56 (-0.14), KPTI: 30.40 (+2.32), HBOS: 26.53 (+0.39)
MEI Pharma anticipates USD45m from public offering of common shares
M2 - Thu Dec 11, 6:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) announced on Wednesday that it intends to offer up to USD45m shares of its common stock in a public offering.
MEIP: 6.06 (-0.07)
MEI Pharma Announces $45 Million Proposed Public Offering of Common Stock
PR Newswire - Wed Dec 10, 3:01PM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer up to $45,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
MEIP: 6.06 (-0.07)
